Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.
Medicare to negotiate prices for top drugs
Medicare announced plans to negotiate lower prices for 15 costly drugs, including Ozempic, Wegovy, and Trelegy Ellipta, starting in 2027. These medications, used for conditions like diabetes, weight loss, and asthma, accounted for $41 billion in Medicare spending last year. Novo Nordisk’s drugs alone cost $14.4 billion.
USA TODAY on MSN13d
Medicare caps seniors drug expenses: What you need to knowMedicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs. The cap ...
The median wait time between referral and appointment was 34 days, and 18 percent of patients waited more than 90 days, the ...
The baby boomer generation is undoubtedly the most important demographic for most investors to consider, from a sheer size ...
Medicare premiums and deductibles have increased for all retirees. There's now a $2,000 cap on annual out-of-pocket ...
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...
A federal mandate that would've required more staffing at nursing homes was met with resistance from industry groups and top attorneys in more than a dozen states including Virginia.
With morale at a low point, biotech and pharma CEOs are cautiously optimistic about the incoming Trump administration.
This is the second installment of a three-part series on aging and disabilities. In our world of modern medicine, to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback